Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2019. The document serves as a transaction notification regarding dealings by a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them, rather than a periodic financial report.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Exercise of share options followed by a sale.
- Volume: 6,910 shares.
- Exercise Price: £12.0350 per share.
- Sale Price: £17.3318 per share.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses a change in shareholding for Mrs. V A Whyte, the Company Secretary, resulting from the exercise and subsequent sale of options granted on February 22, 2010.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of a specific transaction executed on July 29, 2019, on the London Stock Exchange.
Key Facts for Investor Verification
- The filing confirms the exercise and immediate sale of 6,910 shares by the Company Secretary, Mrs. V A Whyte.
- The transaction occurred on July 29, 2019, with a realized price difference between the exercise price (£12.0350) and the sale price (£17.3318).
- This document does not contain quarterly or annual financial results; investors should refer to Form 20-F or other periodic reports for corporate performance data.